Skip to main content

Table 2 List of pathogenic CNVs

From: Genomic imbalances defining novel intellectual disability associated loci

Patients

Gender

Alteration (Hg19)

Type

Size (Mb)

Genes

Key gene(s) involved

Associated syndrome

Phenotype overlap

Inheritance

Confirmation

Array platform

Ref

R1

Male

arr 1p36.23-p36.21(8,593,674-15,396,672)x1dn

del

6.7

86

ANGPTL7, CASZ1, MAD2L2, RERE

–

–

de novo

NP

1

–

R2

Male

arr 2p13.1-p13.3(70,894,906-74,986,518)x1dnc

del

4

62

CYP26B1, EXOC6B

–

–

de novo

NP

1

Wen J, 2013

R3

Male

arr 3q22.1-q23(131,415,639-141,618,552)x1dn

del

1.020

65

FOXL2

BPES

Yes (eye features)

de novo

NP

1

–

C1

Male

arr 5p15.33-p15.32(204,849-5,014,883)x1

del

4.81

30

TERT [CTNND2 not involved]

–

–

ND

NP

2

–

R4

Male

arr 6q25.3(156,012,754-158,804,494)x1dnc

del

2.6

14

ARID1B

Coffin-Siris syndrome

Yes

de novo

NP

1

Santen GW, 2013

C2

Male

arr 7q11.23(72,721,760-74,140,846)x1

del

1.419

28

BAZ1B, STX1A, WBSCR22, ELN

Williams-Beuren syndrome

Partially

ND

NP

2

–

R5

Female

arr 8p23.1(7,039,276-12,485,558)x1dn

del

5.5

70

SOX7, GATA4

8p23.1 deletion syndrome

Yes (cardiac)

de novo

NP

1

–

C3

Male

arr 11q24.2-q25(125,232,584-134,446,160)x1dn

del

9.214

54

KIRREL3, ETS1, FLI1, KCNJ1, KCNJ5, RICS

–

Partially

de novo

qPCR

2

–

R6

Female

arr 12q24.21-q24.22(115,505,500-117,441,683)x1dnc

del

0.2

10

MED13L

–

Yes

de novo

qPCR

1

Adegbola A, 2015

C4

Male

arr 16p11.2(29,674,336-30,198,123)x1dn

del

0.524

29

KCTD13

16p11.2 deletion syndrome

–

de novo

NP

2

–

C5

Male

arr 17q21.31(43,710,371-44,215,352)x1

del

0.505

8

CRHR1, MAPT, STH, and part of the KIAA1267 (KANSL1)

17q21.31 deletion syndrome (Koolen-De Vries syndrome)

–

ND

NP

3

–

C6

Male

arr 22q11.21(18,894,835-21,505,417)x1

del

2.611

59

TBX1

22q11 deletion syndrome

–

ND

NP

2

–

C7

Male

arr 22q13.3(49,513,903-51,178,264)x1

del

1.664

39

SHANK3

22q13.3 deletion syndrome (Phelan-McDermid syndrome)

Partially

ND

NP

2

–

C8

Male

arr 1q21.1q21.2(146,106,723-147,830,830)x3dn

dup

1.7

17

HYDIN2, PRKAB2

1q21.1 duplication syndrome e

Partially

de novo

qPCR

4

–

R7

Male

arr 1q21.1(145,883,119-148,828,690)x3pat

dup

2.5

23

HYDIN2, PRKAB2, GJA5

1q21.1 duplication syndrome e

Yes

paternal

NP

1

–

R8

Male

arr 12q24.21(116,408,736-116,704,303)x3dnc

dup

0.3

2

MED13L

–

Yes

de novo

qPCR

1

Adegbola A, 2015

C9

Male

arr 13q12.12-q34(23,749,431-115,083,342)x2.15a

dup

91.33

##

–

Trisomy 13 (mosaicism)

Yes

ND

Karyotyped

2

–

C10

Female

arr 15q11.2-q13.1(22880274–29,331,964)x3mat

dup

6.45

111

CYF1P1, NIPA2, NIPA1, MKRN3, NDN, MAGEL2, SNURF/SNRPN, UBE3A GABRB3

15q11-q13 duplication syndromeb

Yes

maternal

NP

2

–

C11

Female

arr 16p13.11(15,034,010-16,199,882)x3

dup

1.166

11

NDE1

16p13.11 duplication syndrome e

–

ND

NP

5

–

R9

Male

arr 16p13.11(15,421,671-16,443,968)x3mat

dup

1

19

NDE1

16p13.11 duplication syndrome e

Yes

maternal

NP

1

–

R10

Male

arr 16p13.11(15,484,180-16,308,344)x3mat

dup

0.8

9

NDE1

16p13.11 duplication syndrome e

Yes

maternal

NP

1

–

C12

Male

arr 21q11.2-q22.11(14,417,523-34,894,625)x3

dup

20.47

110

DSCR1, DSCR2, DSCR3, DSCR4, APP

–

No

ND

NP

2

–

R11

Male

arr Xp11.22(53,569,653-53,769,748)x2mat

dup

0.2

3

HUWE1

–

Yes

maternal

qPCR

1

–

R12

Male

arr Xq28(152,348,378-155,228,013)x2dn

dup

2.8

78

MECP2

MECP2 duplication syndrome

Yes

de novo

NP

1

–

R13

Male

arr Xq28(153,130,545-153,602,293)x2mat

dup

0.5

16

MECP2

MECP2 duplication syndrome

Yes

maternal

NP

1

–

R14

Male

arr 9q34.13-q34.3(135,767,911-141,153,431)x3dn

dup

5.516

135

EHMT1, RXRA, GRIN1, UAP1L1

9q34 duplication syndrome

Partially

de novo

NP

1

–

arr 14q32.31-q32.33(102,959,110-104,578,612)x3dn

dup

1.620

22

MARK3, KLC1, EIF5

–

–

de novo

NP

1

–

arr 14q32.33(105,104,831-106,531,339)x3dn

dup

1.427

24

–

–

de novo

NP

1

–

  1. Patients R1 to R14: from research cohort; Patients C1 to C12: from clinical cohort; NP Not performed, ND Not determined; (a): mosaicism; (b) methylation status for SNRPN is normal (studied by MLPA); (c): Published in detail elsewhere; (d): karyotype revealed a balanced translocation between chromosomes 13 and 14, resulting in mosaic trisomy 13; (e): Other causes of disease were not excluded therefore the variant might not explain the total phenotypic presentation. Array platform 1: Agilent 180 K; 2: KaryoArray®v3.0 (Agilent 8x60k); 3: Affymetrix CytoScan HD array; 4: Affymetrix CytoScan 750 K; 5: Agilent Whole Genome 244 K